Acute Myeloid Leukemia (AML)

B. Douglas Smith is Professor of Oncology at Johns Hopkins University School of Medicine in Baltimore, Maryland, and is on the active staff of Johns Hopkins Hospital. He earned his medical degree at the Medical College of Pennsylvania in Philadelphia, after which he completed an internship, residency, and chief residency at Strong Memorial Hospital in Rochester, New York. At the completion of his fellowship in Oncology at Johns Hopkins University, he joined the faculty in the Division of Hematologic Malignancies. Dr. Smith’s research focuses on taking new and promising laboratory insights and

Dr. Rossetti earned his Doctor of Osteopathic Medicine degree from the Lake Erie College of Osteopathic Medicine and completed an internship and internal medicine residency at St. Francis Medical Center of Pittsburgh. He did fellowship training in hematology and medical oncology at The Western Pennsylvania Hospital and is board certified in medical oncology and hematology. He is an assistant professor at the Temple University School of Medicine and an adjunct clinical instructor for the Lake Erie College of Osteopathic Medicine. Dr. Rossetti is a recognized expert in hematological malignancy

Dr. Michael Keng holds a clinical faculty appointment in Medicine in the Division of Hematology/Oncology at UVA Cancer Center. He practices at the Emily Couric Clinical Cancer Center in Charlottesville and serves as an inpatient hematologist at UVA Hospital. His clinical areas of interest are: myelodysplastic syndromes, myeloproliferative disorders, acute myeloid leukemia, chronic myeloid leukemia, acute lymphoid leukemia, and aplastic anemia. He attended medical school at Michigan State University in East Lansing, Michigan and completed internal medicine residency at University of Southern

Dr. Robert Coleman Lindsley, M.D., PhD. is a physician scientist at Dana-Farber Cancer Institute, specializing in research topics associated with MDS. His career has developed in conjunction with his interest in how disease evolves, and in turn, how new and existing therapies can interrupt the process of disease progression. The clinical research focus he has chosen in addressing problems with MDS has led to work in two important areas; examining how the fundamental properties of MDS change over time, and the features of MDS that cause resistance to therapy. Dr. Lindsley’s efforts include

Maria Baer joined the University of Maryland Marlene and Stewart Greenebaum Cancer Center in Baltimore, Maryland in 2007 as director of hematologic malignancies and professor of medicine and molecular medicine, University of Maryland School of Medicine. She previously served as chief of the leukemia section at Roswell Park Cancer Institute and professor of medicine and associate professor of molecular pharmacology and cancer therapeutics at the University at Buffalo School of Medicine and Biomedical Sciences in Buffalo, New York.

Dr. Becker is pursuing several areas of research investigation, including 1) the mechanism of adhesion mediated chemotherapy resistance in acute myeloid leukemia and 2) hematopoietic stem cell gene transfer for a genetic disorder of DNA repair, Fanconi anemia. TODO: Above paragraph was copied from online profile, may need to be edited.

Mikkael A. Sekeres, MD, MS has been Medical Advisory Board Co-Chair since 2004. He is currently the Physician Liaison in Hematology and Chief of the Division of Hematology at the Sylvester Comprehensive Center at the University. Previously, Dr. Sekeres was the professor of medicine, director of the leukemia program, and Vice Chair for Clinical Research at the Cleveland Clinic Taussig Cancer Institute in Ohio. He earned his medical degree and a master’s degree in clinical epidemiology from the University of Pennsylvania School of Medicine. Dr. Sekeres completed his postgraduate training at